重组人脑利钠肽联合盐酸艾司洛尔治疗急性心肌梗死伴心衰患者疗效观察

Observation on the Therapeutic Effect of Recombinant Human Brain Natriuretic Peptide Combined with Esmolol Hydrochloride on Acute Myocardial Infarction Patients with Heart Failure

目的探讨重组人脑利钠肽、盐酸艾司洛尔联合治疗急性心肌梗死伴心衰的临床效果。方法选取急性心肌梗死伴心衰患者71例,按治疗方案不同分联合组和常规组。常规组予以盐酸艾司洛尔治疗,联合组予以重组人脑利钠肽、盐酸艾司洛尔联合治疗。对比两组疗效、不良反应、治疗前后血清N末端心房利钠肽(NT-proBNP)、内皮素-1(ET-1)水平。结果联合组总有效率91.67%较常规组71.43%高(P<0.05);治疗后两组血清NT-proBNP、ET-1水平均显著改善,且联合组低于常规组(P<0.05);以确切概率法计算,联合组不良反应发生率2.78%与常规组0.00%对比,差异无统计学意义(P>0.05)。结论重组人脑利钠肽、盐酸艾司洛尔联合治疗急性心肌梗死伴心衰疗效显著,能有效改善血清因子水平,且不良反应少。

Objective To explore the clinical effect of recombinant human brain natriuretic peptide and esmolol hydrochloride in the treatment of acute myocardial infarction with heart failure.Methods 71 patients with acute myocardial infarction and heart failure were selected and were divided into combined group and conventional group according to different treatment schemes.The routine group was treated with esmolol hydrochloride,and the combined group was treated with recombinant human brain natriuretic peptide and esmolol hydrochloride.The efficacy,adverse reactions,serum N-terminal atrial natriuretic peptide(NT-proBNP)and endothelin-1(ET-1)levels before and after treatment were compared between the two groups.Results The total effective rate of the combined group was 91.67%higher than that of the conventional group 71.43%(P<0.05).After treatment,the serum NT-proBNP and ET-1 levels of the two groups were significantly improved,and the combined group was lower than that of the conventional group(P<0.05).According to the exact probability method,the incidence of adverse reactions in the combined group was 2.78%and 0.00%compared with the conventional group,there was no significant difference(P>0.05).Conclusion The combination of recombinant human brain natriuretic peptide and esmolol hydrochloride is effective in the treatment of acute myocardial infarction with heart failure,and can effectively improve the serum factor level with fewer adverse reactions.